Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Pharmacology

Background:

• Histone deacetylase (HDAC) inhibitors are critical for managing acetylation/deacetylation balance in histones and non-histone proteins.
• HDACs represent significant epigenetic targets, with their inhibitors being key compounds in cancer treatment.
• Recent advancements focus on selective and multitarget HDAC inhibitors.

Purpose of the Study:

• To review recent advancements in the synthesis and application of HDAC inhibitors and hybrid inhibitors.
• To highlight the progress and challenges in developing novel HDAC inhibitors.
• To explore emerging therapeutic applications of HDAC inhibitors beyond cancer.

Main Methods:

• Literature review of scientific publications and patents from 2017-2019.
• Analysis of synthetic strategies for novel HDAC inhibitors.
• Evaluation of therapeutic applications and pharmacokinetic profiles.

Main Results:

• Significant progress in developing selective and multitarget HDAC inhibitors.
• Identification of a need for novel zinc-binding groups to overcome pharmacokinetic limitations of hydroxamic acids.
• Exploration of HDAC inhibitors for treating alcohol use disorder, neurological disorders, and age-related diseases.

Conclusions:

• HDAC inhibitors are crucial in cancer therapy and show promise for other diseases.
• Development of novel HDAC inhibitors with improved pharmacokinetic profiles is essential.
• Continued research into HDAC inhibitors offers new therapeutic strategies for various human conditions.